Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: Final results of the TEMAVIR study from ANOCEF

Annals of Oncology

Volumn 25, Issue 7, 2014, Pages 1442-1447

  Chauffer, Bruno ^a   Feuvret, L ^b   Bonnetain, F ^c   Taillandier, L ^d   Frappaz, D ^e   Taillia, H ^f   Schott, R ^g   Honnorat, J ^h   Fabbro, M ⁱ   Tennevet, I ^j   Ghiringhelli, F ^k   Guillamo, J S ^l   Durando, X ^m   Castera, D ⁿ   Frenay, M ^o   Campello, C ^p   Dalban, C ^k   Skrzypski, J ^k   Chinot, O ^q  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c UNIVERSITY HOSPITAL OF BESANÇON   (France)

^d UNIVERSITY HOSPITAL OF NANCY   (France)

^e CENTRE LÉON BÉRARD   (France)

^f Val d'Aurelle Center for Fight against Cancer ^*  (France)

^g Regional Paul Strauss Cancer Centre   (France)

^h Department of Neurosciences   (France)

ⁱ CENTRE VAL D AURELLE   (France)

^j CENTRE HENRI BECQUEREL   (France)

^k Methodology Unit   (France)

^l CAEN UNIVERSITY HOSPITAL   (France)

^m CENTRE JEAN PERRIN   (France)

ⁿ Clinique Saint Pierre   (France)

^o CENTRE ANTOINE LACASSAGNE   (France)

^p NÎMES UNIVERSITY HOSPITAL   (France)

^q TIMONE HOSPITAL   (France)

more..

Author keywords

Bevacizumab; Glioblastoma; Irinotecan; Radiotherapy; Temozolomide

Indexed keywords

BEVACIZUMAB; IRINOTECAN; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DACARBAZINE; MONOCLONAL ANTIBODY;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ANEMIA; APLASIA; ARTERIAL ISCHEMIA; ARTICLE; BILE DUCT DISEASE; BLOOD TOXICITY; BRAIN HEMORRHAGE; CANCER GROWTH; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL INFECTION; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; HUMAN; HYPERTENSION; INOPERABLE CANCER; ISCHEMIA; KARNOFSKY PERFORMANCE STATUS; LUNG EMBOLISM; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; VASCULAR DISEASE; VEIN EMBOLISM; ADJUVANT CHEMOTHERAPY; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; CLINICAL TRIAL; MIDDLE AGED;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; DACARBAZINE; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED;

EID: 84903745672     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu148     Document Type: Article

References (13)

1. Chauffert B, Feuvret L, Bonnetain F, Taillandier L et al. Randomized multicenter phase II trial of irinotecan and bevacizumab as neoadjuvant and adjuvant to temozolomide-based chemoradiation versus chemoradiation for unresectable glioblastoma: Definitive results of the TEMAVIR ANOCEF study (LBA; ESMO 2012). Ann Oncol 2012; 23: S10 (LBA 15).
2. Stupp R, Mason WP, Van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
3. Mirimanoff RO, Gorlia T, Mason W et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 2006; 24: 2563-2569.
4. Vredenburgh JJ, Desjardins A, Herndon JE et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiform. J Clin Oncol 2007; 25: 4722-4729.
5. Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. Br J Cancer 1991; 64: 769-774.
6. Macdonald DR, Cascino TL, Schold SC, Jr et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8: 1277-1280.
7. Curran WJ, Jr, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant gliomatrials. J Natl Cancer Inst 1993; 85: 704-710.
8. Chinot OL, Wick W, Mason W et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014; 370: 709-722.
9. Gilbert MR, Dignam JJ, Armstrong TS et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014; 370: 699-708.
10. Stummer W, Van den Bent M, Westphal M et al. Cytoreductive surgery of glioblasotoma as the key to successful adjuvant therapies: new arguments in an old discussion. Acta Neurochir 2011; 153: 1211-1218.
11. Scott CB, Scarantino C, Urtasun R et al. Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys 1998; 40: 51-55.
12. Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27: 4733-4740.
13. Fine HA. Bevacizumab in glioblastoma-still much to learn. N Engl J Med 2014; 370: 764-765.